Day: May 9, 2022

ANNOUNCEMENT NO. 113 – 9 MAY 2022 Under Article 19 of the Market Abuse Regulation Dampskibsselskabet NORDEN A/S is required to report transactions in Dampskibsselskabet NORDEN A/S’ shares by persons discharging managerial responsibilities and their close relatives.Name:   Jan RindboReason:   Reporting duty, CEOIssuer:   Dampskibsselskabet NORDEN A/SISIN code:   DK0010269844Instrument:   SharesTransaction:   Exercise of share optionsTrading date:   5 May 2022Market:   Nasdaq CopenhagenNumber:   50,000Market value in DKK   5,744,500Holding after transaction   149,937Name:   Jan RindboReason:   Reporting duty, CEOIssuer:   Dampskibsselskabet NORDEN A/SISIN code:   DK0010269844Instrument:   SharesTransaction:   Sale of sharesTrading date:   5 May 2022Market:   Nasdaq CopenhagenNumber:   10,000Market...

NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES. NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON IN ANY JURISDICTION WHERE RELEASE, PUBLICATION OR DISTRIBUTION TO SUCH PERSON IS RESTRICTED BY ANY LAW OR REGULATION APPLICABLE IN SUCH JURISDICTION. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR ISSUE OR INVITATION TO PURCHASE OR SUBSCRIBE FOR, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES. Coloplast has today established a Euro Medium Term Note Programme (the “EMTN Programme“). The EMTN Programme provides a framework for issuances of senior unsecured notes up to an aggregate principal amount of EUR 3.5 billion by Coloplast and a newly formed subsidiary, Coloplast Finance B.V. (“Coloplast Finance“)....

Oslo,9 May 2022: Snorre Valdimarsson, EVP General Counsel of Scatec ASA has on 9 May bought 2,198 shares in Scatec ASA at an average price per share of NOK 90.96. Attached is the notification of the transaction in accordance with the Market Abuse Regulation Article 19. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading act.AttachmentNotification of transaction_090522 KRT 1500 Valdimarsson

        Company Announcement No 20/2022Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk9 May 2022  Dear Sirs Sydbank share buyback programme: transactions in week 18On 2 March 2022 Sydbank announced a share buyback programme of DKK 425m. The share buyback commenced on 7 March 2022 and will be completed by 30 December 2022. The purpose of the share buyback programme is to reduce the share capital of Sydbank and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules. The following transactions have been made under the share buyback programme:  Number...

The EolMed partnership, comprising Qair, Totalenergies and BW Ideol, has made the final investment decision (FID) today for its 30MW offshore floating wind development. The Mediterranean Sea pilot wind farm is set to become one of the first three floating offshore wind farms in France when it is commissioned in mid-2024. “This is a major milestone for the EolMed project and for BW Ideol. Today’s decision to proceed with the construction and installation of the wind farm that was never challenged by legal recourse, reflects years of planning and preparation. As both project co-developer and provider of the floating  technology and the related engineering services, we are delivering on our dual strategy, reinforcing our floating wind market leadership in France and favorably positioning ourselves for the upcoming French Mediterranean floating...

ORION CORPORATION                 PRESS RELEASE                 9 May 2022 at 10.00 EEST The negotiations under the Act on Co-operation within Undertakings concerning Orion’s R&D have been completed – future focus on pain and oncology Orion announced on 24 March 2022 that it is planning to refocus the strategy of its R&D function. In the future, Orion will invest in the research and development of new proprietary drugs in two therapy areas: cancer diseases and pain. The negotiations under the Act on Co-operation within Undertakings in Finland related to the changes have been completed. As a result, 32 people will be made redundant, six of whom will be offered positions elsewhere in the Orion Group. The company believes that by focusing its resources, it will be able to develop new treatments for patients’ needs and generate the...